<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00881894</url>
  </required_header>
  <id_info>
    <org_study_id>SP0951</org_study_id>
    <nct_id>NCT00881894</nct_id>
  </id_info>
  <brief_title>Study in Healthy Volunteers to Prove That 2 Rotigotine Patches From Different Manufacturing Processes Deliver Equivalent Drug Amount to the Body.</brief_title>
  <official_title>Single-site, Open-label, Randomized, Cross-over Trial to Evaluate the Bioequivalence of Single Dose Rotigotine Transdermal Patch (4.5mg/10cm^2) From 2 Different Manufacturing Processes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The major aim of this study is to investigate and compare the drug amount delivered to the
      body after sequential application of 2 rotigotine transdermal patches from 2 different
      manufacturing processes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC(0-tz) of Unconjugated Rotigotine</measure>
    <time_frame>Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application</time_frame>
    <description>The AUC(0-tz) is the area under the plasma concentration- time curve from zero up to the last analytically quantifiable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Unconjugated Rotigotine</measure>
    <time_frame>Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.</time_frame>
    <description>The Cmax is the maximum plasma concentration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC(0-∞) of Unconjugated Rotigotine</measure>
    <time_frame>Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.</time_frame>
    <description>The AUC(0-∞) is the area under the plasma concentration- time curve from zero up to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-tz)Norm (Apparent Dose) of Unconjugated Rotigotine</measure>
    <time_frame>Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.</time_frame>
    <description>The AUC(0-tz)Norm (Apparent dose) is the area under the plasma concentration- time curve from zero up to the last analytically quantifiable concentration normalized by apparent dose (mg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-tz)Norm (BW) of Unconjugated Rotigotine</measure>
    <time_frame>Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.</time_frame>
    <description>The AUC(0-tz)Norm (BW) is the area under the plasma concentration- time curve from zero up to the last analytically quantifiable concentration normalized by body weight (kg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,Norm (Apparent Dose) of Unconjugated Rotigotine</measure>
    <time_frame>Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.</time_frame>
    <description>The Cmax,Norm (Apparent dose) is the maximum plasma concentration normalized by apparent dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,Norm (BW) of Unconjugated Rotigotine</measure>
    <time_frame>Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.</time_frame>
    <description>The Cmax,Norm (BW) is the maximum plasma concentration normalized by body weight (kg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Unconjugated Rotigotine</measure>
    <time_frame>Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.</time_frame>
    <description>The Tmax is the time to reach a maximum plasma concentration after patch application.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT of Unconjugated Rotigotine</measure>
    <time_frame>Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24(before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.</time_frame>
    <description>The MRT is the mean residence time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz of Unconjugated Rotigotine</measure>
    <time_frame>Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.</time_frame>
    <description>The λz is the rate constant of elimination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Unconjugated Rotigotine</measure>
    <time_frame>Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.</time_frame>
    <description>The t1/2 is the terminal half- life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/f of Unconjugated Rotigotine</measure>
    <time_frame>Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.</time_frame>
    <description>The CL/f is the apparent total body clearance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Dose</measure>
    <time_frame>48 hours</time_frame>
    <description>Apparent dose of unconjugated rotigotine in mg. The Apparent dose of unconjugated rotigotine was determined from the patches removed on Day 2.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sequence A-B (Test: PR2.1.1 - Reference: PR1.0)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two single applications of rotigotine patches from two different manufacturing processes in the order A-B separated by a washout phase of at least 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B-A (Reference: PR1.0 - Test: PR2.1.1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two single applications of rotigotine patches from two different manufacturing processes in the order B-A separated by a washout phase of at least 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rotigotine transdermal patch</intervention_name>
    <description>Rotigotine 4.5mg/10cm^2 patch applied for 24 hours</description>
    <arm_group_label>Sequence A-B (Test: PR2.1.1 - Reference: PR1.0)</arm_group_label>
    <arm_group_label>Sequence B-A (Reference: PR1.0 - Test: PR2.1.1)</arm_group_label>
    <other_name>Neupro®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy White, male volunteers between 18 and 55 years of age (inclusive).

          -  BMI between 19 and 28 kg/m² (inclusive).

        Exclusion Criteria:

          -  Previous participation in a clinical study with rotigotine

          -  History or current condition of epilepsy and/or seizures.

          -  Known clinically relevant allergy or known/suspected clinically relevant drug
             hypersensitivity.

          -  History of significant skin hypersensitivity to adhesives or other transdermal
             products or recently unresolved contact dermatitis.

          -  History or present condition of an atopic or eczematous dermatitis, psoriasis, and/or
             an active skin disease.

          -  Clinically relevant abnormality in physical examination, ECG, vital signs or safety
             laboratory examinations.

          -  Positive HIV, hepatitis B or C test or positive alcohol or drug test.

          -  Relevant hepatic or renal dysfunction

          -  Intake of medication that might interfere with the test drug within 2 weeks prior to
             dosing.

          -  Thickly hair-covered abdomen resulting in difficulties in finding appropriate patch
             application sites
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Neuss</city>
        <state>NRW</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2009</study_first_submitted>
  <study_first_submitted_qc>April 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2009</study_first_posted>
  <results_first_submitted>November 20, 2009</results_first_submitted>
  <results_first_submitted_qc>November 20, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 25, 2009</results_first_posted>
  <last_update_submitted>October 17, 2014</last_update_submitted>
  <last_update_submitted_qc>October 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rotigotine</keyword>
  <keyword>Neupro®</keyword>
  <keyword>Transdermal Patch</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rotigotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 52, healthy, male subjects has been randomized in order to complete the trial with at least 44 subjects eligible for the Pharmacokinetic Set (PKS). Baseline characteristics refer to the PKS.</recruitment_details>
      <pre_assignment_details>Patients with an insufficient patch adhesiveness were excluded from the PKS.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence A-B (Test: PR2.1.1 - Reference: PR1.0)</title>
          <description>Two single applications of rotigotine patches from two different manufacturing processes in the order A-B separated by a washout phase of at least 5 days</description>
        </group>
        <group group_id="P2">
          <title>Sequence B-A (Reference: PR1.0 - Test: PR2.1.1)</title>
          <description>Two single applications of rotigotine patches from two different manufacturing processes in the order B-A separated by a washout phase of at least 5 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Pharmacokinetic Set (PKS)</title>
              <participants_list>
                <participants group_id="P1" count="23">Patients with an insufficient patch adhesiveness were excluded from the PKS.</participants>
                <participants group_id="P2" count="21">Patients with an insufficient patch adhesiveness were excluded from the PKS.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Consent withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons for premature termination</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sequence A-B (Test: PR2.1.1 - Reference: PR1.0)</title>
          <description>Two single applications of rotigotine patches from two different manufacturing processes in the order A-B separated by a washout phase of at least 5 days</description>
        </group>
        <group group_id="B2">
          <title>Sequence B-A (Reference: PR1.0 - Test: PR2.1.1)</title>
          <description>Two single applications of rotigotine patches from two different manufacturing processes in the order B-A separated by a washout phase of at least 5 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.7" spread="9.8"/>
                    <measurement group_id="B2" value="39.3" spread="9.1"/>
                    <measurement group_id="B3" value="39.0" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.98" spread="7.08"/>
                    <measurement group_id="B2" value="79.98" spread="8.20"/>
                    <measurement group_id="B3" value="79.45" spread="7.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-tz) of Unconjugated Rotigotine</title>
        <description>The AUC(0-tz) is the area under the plasma concentration- time curve from zero up to the last analytically quantifiable concentration.</description>
        <time_frame>Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application</time_frame>
        <population>Pharmacokinetic Set (PKS)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A (Test: PR2.1.1)</title>
            <description>Rotigotine transdermal patch (4.5 mg/ 10 cm^2) from modified manufacturing process (Test; drug product PR2.1.1); single application of 1 patch for 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Treatment B (Reference: PR1.0)</title>
            <description>Rotigotine transdermal patch (4.5 mg/ 10 cm^2) from originally approved manufacturing process (Reference; drug product PR1.0); single application of 1 patch for 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-tz) of Unconjugated Rotigotine</title>
          <description>The AUC(0-tz) is the area under the plasma concentration- time curve from zero up to the last analytically quantifiable concentration.</description>
          <population>Pharmacokinetic Set (PKS)</population>
          <units>(ng/ mL)*h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0168" spread="1.4077"/>
                    <measurement group_id="O2" value="3.0635" spread="1.4309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Bioequivalence testing by using the 90% Confidence Interval (CI).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% Confidence Interval for the ratio of geometric LS- Means is included within 0.8- 1.25, the patches are considered bioequivalent.</non_inferiority_desc>
            <param_type>ratio of geometric LS- Means</param_type>
            <param_value>0.9864</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>0.9103</ci_lower_limit>
            <ci_upper_limit>1.0688</ci_upper_limit>
            <estimate_desc>Bioequivalence is concluded if the 90% CIs for the ratio Treatment A/ Treatment B are fully included in the acceptance range from 0.8- 1.25 for AUC(0-tz) and Cmax.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Unconjugated Rotigotine</title>
        <description>The Cmax is the maximum plasma concentration.</description>
        <time_frame>Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.</time_frame>
        <population>Pharmacokinetic Set (PKS)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A (Test: PR2.1.1)</title>
            <description>Rotigotine transdermal patch (4.5 mg/ 10 cm^2) from modified manufacturing process (Test; drug product PR2.1.1); single application of 1 patch for 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Treatment B (Reference: PR1.0)</title>
            <description>Rotigotine transdermal patch (4.5 mg/ 10 cm^2) from originally approved manufacturing process (Reference; drug product PR1.0); single application of 1 patch for 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Unconjugated Rotigotine</title>
          <description>The Cmax is the maximum plasma concentration.</description>
          <population>Pharmacokinetic Set (PKS)</population>
          <units>ng/ mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14418" spread="0.06211"/>
                    <measurement group_id="O2" value="0.15155" spread="0.06540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Bioequivalence testing by using the 90% Confidence Interval (CI).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% Confidence Interval for the ratio of geometric LS- Means is included within 0.8- 1.25, the patches are considered bioequivalent.</non_inferiority_desc>
            <param_type>ratio of geometric LS- Means</param_type>
            <param_value>0.9584</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>0.8861</ci_lower_limit>
            <ci_upper_limit>1.0367</ci_upper_limit>
            <estimate_desc>Bioequivalence is concluded if the 90% CIs for the ratio Treatment A/ Treatment B are fully included in the acceptance range from 0.8- 1.25 for AUC(0-tz) and Cmax.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-∞) of Unconjugated Rotigotine</title>
        <description>The AUC(0-∞) is the area under the plasma concentration- time curve from zero up to infinity.</description>
        <time_frame>Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.</time_frame>
        <population>Pharmacokinetic Set (PKS)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A (Test: PR2.1.1)</title>
            <description>Rotigotine transdermal patch (4.5 mg/ 10 cm^2) from modified manufacturing process (Test; drug product PR2.1.1); single application of 1 patch for 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Treatment B (Reference: PR1.0)</title>
            <description>Rotigotine transdermal patch (4.5 mg/ 10 cm^2) from originally approved manufacturing process (Reference; drug product PR1.0); single application of 1 patch for 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-∞) of Unconjugated Rotigotine</title>
          <description>The AUC(0-∞) is the area under the plasma concentration- time curve from zero up to infinity.</description>
          <population>Pharmacokinetic Set (PKS)</population>
          <units>(ng/ mL)*h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.12622" spread="1.41536"/>
                    <measurement group_id="O2" value="3.16403" spread="1.43028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Bioequivalence testing by using the 90% Confidence Interval (CI).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% Confidence Interval for the ratio of geometric LS- Means is included within 0.8- 1.25, the patches are considered bioequivalent.</non_inferiority_desc>
            <param_type>ratio of geometric LS- Means</param_type>
            <param_value>0.9896</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>0.9179</ci_lower_limit>
            <ci_upper_limit>1.0671</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-tz)Norm (Apparent Dose) of Unconjugated Rotigotine</title>
        <description>The AUC(0-tz)Norm (Apparent dose) is the area under the plasma concentration- time curve from zero up to the last analytically quantifiable concentration normalized by apparent dose (mg).</description>
        <time_frame>Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.</time_frame>
        <population>Pharmacokinetic Set (PKS)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A (Test: PR2.1.1)</title>
            <description>Rotigotine transdermal patch (4.5 mg/ 10 cm^2) from modified manufacturing process (Test; drug product PR2.1.1); single application of 1 patch for 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Treatment B (Reference: PR1.0)</title>
            <description>Rotigotine transdermal patch (4.5 mg/ 10 cm^2) from originally approved manufacturing process (Reference; drug product PR1.0); single application of 1 patch for 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-tz)Norm (Apparent Dose) of Unconjugated Rotigotine</title>
          <description>The AUC(0-tz)Norm (Apparent dose) is the area under the plasma concentration- time curve from zero up to the last analytically quantifiable concentration normalized by apparent dose (mg).</description>
          <population>Pharmacokinetic Set (PKS)</population>
          <units>(ng/ mL)*(h/ mg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78200" spread="0.71912"/>
                    <measurement group_id="O2" value="1.58900" spread="0.54806"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-tz)Norm (BW) of Unconjugated Rotigotine</title>
        <description>The AUC(0-tz)Norm (BW) is the area under the plasma concentration- time curve from zero up to the last analytically quantifiable concentration normalized by body weight (kg).</description>
        <time_frame>Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.</time_frame>
        <population>Pharmacokinetic Set (PKS)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A (Test: PR2.1.1)</title>
            <description>Rotigotine transdermal patch (4.5 mg/ 10 cm^2) from modified manufacturing process (Test; drug product PR2.1.1); single application of 1 patch for 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Treatment B (Reference: PR1.0)</title>
            <description>Rotigotine transdermal patch (4.5 mg/ 10 cm^2) from originally approved manufacturing process (Reference; drug product PR1.0); single application of 1 patch for 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-tz)Norm (BW) of Unconjugated Rotigotine</title>
          <description>The AUC(0-tz)Norm (BW) is the area under the plasma concentration- time curve from zero up to the last analytically quantifiable concentration normalized by body weight (kg).</description>
          <population>Pharmacokinetic Set (PKS)</population>
          <units>(ng/ mL)*h*kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239.241" spread="112.475"/>
                    <measurement group_id="O2" value="243.841" spread="116.640"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax,Norm (Apparent Dose) of Unconjugated Rotigotine</title>
        <description>The Cmax,Norm (Apparent dose) is the maximum plasma concentration normalized by apparent dose.</description>
        <time_frame>Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.</time_frame>
        <population>Pharmacokinetic Set (PKS)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A (Test: PR2.1.1)</title>
            <description>Rotigotine transdermal patch (4.5 mg/ 10 cm^2) from modified manufacturing process (Test; drug product PR2.1.1); single application of 1 patch for 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Treatment B (Reference: PR1.0)</title>
            <description>Rotigotine transdermal patch (4.5 mg/ 10 cm^2) from originally approved manufacturing process (Reference; drug product PR1.0); single application of 1 patch for 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax,Norm (Apparent Dose) of Unconjugated Rotigotine</title>
          <description>The Cmax,Norm (Apparent dose) is the maximum plasma concentration normalized by apparent dose.</description>
          <population>Pharmacokinetic Set (PKS)</population>
          <units>(ng/ mL) / mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.085822" spread="0.032789"/>
                    <measurement group_id="O2" value="0.079619" spread="0.027178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax,Norm (BW) of Unconjugated Rotigotine</title>
        <description>The Cmax,Norm (BW) is the maximum plasma concentration normalized by body weight (kg).</description>
        <time_frame>Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.</time_frame>
        <population>Pharmacokinetic Set (PKS)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A (Test: PR2.1.1)</title>
            <description>Rotigotine transdermal patch (4.5 mg/ 10 cm^2) from modified manufacturing process (Test; drug product PR2.1.1); single application of 1 patch for 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Treatment B (Reference: PR1.0)</title>
            <description>Rotigotine transdermal patch (4.5 mg/ 10 cm^2) from originally approved manufacturing process (Reference; drug product PR1.0); single application of 1 patch for 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax,Norm (BW) of Unconjugated Rotigotine</title>
          <description>The Cmax,Norm (BW) is the maximum plasma concentration normalized by body weight (kg).</description>
          <population>Pharmacokinetic Set (PKS)</population>
          <units>(ng/ mL)*kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4391" spread="4.9667"/>
                    <measurement group_id="O2" value="12.0441" spread="5.3133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax of Unconjugated Rotigotine</title>
        <description>The Tmax is the time to reach a maximum plasma concentration after patch application.</description>
        <time_frame>Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.</time_frame>
        <population>Pharmacokinetic Set (PKS)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A (Test: PR2.1.1)</title>
            <description>Rotigotine transdermal patch (4.5 mg/ 10 cm^2) from modified manufacturing process (Test; drug product PR2.1.1); single application of 1 patch for 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Treatment B (Reference: PR1.0)</title>
            <description>Rotigotine transdermal patch (4.5 mg/ 10 cm^2) from originally approved manufacturing process (Reference; drug product PR1.0); single application of 1 patch for 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Unconjugated Rotigotine</title>
          <description>The Tmax is the time to reach a maximum plasma concentration after patch application.</description>
          <population>Pharmacokinetic Set (PKS)</population>
          <units>hour (h)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.00" spread="6.18" lower_limit="8.0" upper_limit="28.0"/>
                    <measurement group_id="O2" value="16.00" spread="5.26" lower_limit="6.0" upper_limit="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MRT of Unconjugated Rotigotine</title>
        <description>The MRT is the mean residence time.</description>
        <time_frame>Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24(before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.</time_frame>
        <population>Pharmacokinetic Set (PKS)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A (Test: PR2.1.1)</title>
            <description>Rotigotine transdermal patch (4.5 mg/ 10 cm^2) from modified manufacturing process (Test; drug product PR2.1.1); single application of 1 patch for 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Treatment B (Reference: PR1.0)</title>
            <description>Rotigotine transdermal patch (4.5 mg/ 10 cm^2) from originally approved manufacturing process (Reference; drug product PR1.0); single application of 1 patch for 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>MRT of Unconjugated Rotigotine</title>
          <description>The MRT is the mean residence time.</description>
          <population>Pharmacokinetic Set (PKS)</population>
          <units>hour (h)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.012" spread="1.809"/>
                    <measurement group_id="O2" value="18.882" spread="1.802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>λz of Unconjugated Rotigotine</title>
        <description>The λz is the rate constant of elimination.</description>
        <time_frame>Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.</time_frame>
        <population>Pharmacokinetic Set (PKS)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A (Test: PR2.1.1)</title>
            <description>Rotigotine transdermal patch (4.5 mg/ 10 cm^2) from modified manufacturing process (Test; drug product PR2.1.1); single application of 1 patch for 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Treatment B (Reference: PR1.0)</title>
            <description>Rotigotine transdermal patch (4.5 mg/ 10 cm^2) from originally approved manufacturing process (Reference; drug product PR1.0); single application of 1 patch for 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>λz of Unconjugated Rotigotine</title>
          <description>The λz is the rate constant of elimination.</description>
          <population>Pharmacokinetic Set (PKS)</population>
          <units>1/ hour (1/h)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.153848" spread="0.037525"/>
                    <measurement group_id="O2" value="0.151239" spread="0.025301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2 of Unconjugated Rotigotine</title>
        <description>The t1/2 is the terminal half- life.</description>
        <time_frame>Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.</time_frame>
        <population>Pharmacokinetic Set (PKS)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A (Test: PR2.1.1)</title>
            <description>Rotigotine transdermal patch (4.5 mg/ 10 cm^2) from modified manufacturing process (Test; drug product PR2.1.1); single application of 1 patch for 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Treatment B (Reference: PR1.0)</title>
            <description>Rotigotine transdermal patch (4.5 mg/ 10 cm^2) from originally approved manufacturing process (Reference; drug product PR1.0); single application of 1 patch for 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 of Unconjugated Rotigotine</title>
          <description>The t1/2 is the terminal half- life.</description>
          <population>Pharmacokinetic Set (PKS)</population>
          <units>hour (h)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7665" spread="1.1499"/>
                    <measurement group_id="O2" value="4.7128" spread="0.8088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CL/f of Unconjugated Rotigotine</title>
        <description>The CL/f is the apparent total body clearance.</description>
        <time_frame>Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.</time_frame>
        <population>Pharmacokinetic Set (PKS)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A (Test: PR2.1.1)</title>
            <description>Rotigotine transdermal patch (4.5 mg/ 10 cm^2) from modified manufacturing process (Test; drug product PR2.1.1); single application of 1 patch for 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Treatment B (Reference: PR1.0)</title>
            <description>Rotigotine transdermal patch (4.5 mg/ 10 cm^2) from originally approved manufacturing process (Reference; drug product PR1.0); single application of 1 patch for 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>CL/f of Unconjugated Rotigotine</title>
          <description>The CL/f is the apparent total body clearance.</description>
          <population>Pharmacokinetic Set (PKS)</population>
          <units>L/ h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1825.38" spread="1058.21"/>
                    <measurement group_id="O2" value="1822.13" spread="1060.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Dose</title>
        <description>Apparent dose of unconjugated rotigotine in mg. The Apparent dose of unconjugated rotigotine was determined from the patches removed on Day 2.</description>
        <time_frame>48 hours</time_frame>
        <population>Pharmacokinetic Set (PKS)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A (Test: PR2.1.1)</title>
            <description>Rotigotine transdermal patch (4.5 mg/ 10 cm^2) from modified manufacturing process (Test; drug product PR2.1.1); single application of 1 patch for 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Treatment B (Reference: PR1.0)</title>
            <description>Rotigotine transdermal patch (4.5 mg/ 10 cm^2) from originally approved manufacturing process (Reference; drug product PR1.0); single application of 1 patch for 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Dose</title>
          <description>Apparent dose of unconjugated rotigotine in mg. The Apparent dose of unconjugated rotigotine was determined from the patches removed on Day 2.</description>
          <population>Pharmacokinetic Set (PKS)</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.676" spread="0.423"/>
                    <measurement group_id="O2" value="1.890" spread="0.561"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) were collected within 48 hours.</time_frame>
      <desc>Adverse events are reported for the Safety Set (SS). The SS includes all randomized subjects who received at least 1 dose of trial medication (N=52). Two subjects terminated the study prematurely after period 1 (1 subject in sequence A-B and 1 in sequence B-A). Therefore the number of subject exposed to each treatment is N=51.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment A (Test: PR2.1.1)</title>
          <description>Rotigotine transdermal patch (4.5 mg/ 10 cm^2) from modified manufacturing process (Test; drug product PR2.1.1); single application of 1 patch for 24 hours</description>
        </group>
        <group group_id="E2">
          <title>Treatment B (Reference: PR1.0)</title>
          <description>Rotigotine transdermal patch (4.5 mg/ 10 cm^2) from originally approved manufacturing process (Reference; drug product PR1.0); single application of 1 patch for 24 hours</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Sensation in Eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application Site Pruritus</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="51"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Application Site Cold Feeling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Syncope Vasovagal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Disturbance in Attention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>UCB has &gt; 60 days but &lt;= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>UCB Clinical Trial Call Center</name_or_title>
      <organization>UCB</organization>
      <phone>+1 877 822 9493</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

